TLX price $9.53 +0.27 +2.92%
Insights · Dividends · Forecast · Financials · Learn
The Telix Pharmaceuticals (TLX) forecast collects the published price target, analyst ratings, and earnings estimates when they are available.
Forecasts are third-party estimates and often wrong. They are not investment advice.
A low, average, and high target are shown in the tool when analysts have published them.
A Buy, Hold, and Sell split is shown when analysts have published ratings. It is not a recommendation.
EPS and revenue estimates for the coming years are drawn in the chart when analysts have published them.
The Stocklytics Score, when it is published for TLX, averages value, quality, and growth on a 0–100 scale. It is not a price target. Fair value is a separate estimate on the fair value tab.
A 12-month average target is shown on this page when analysts have published one.
A consensus is shown when analysts have published ratings. It is not a recommendation.
An EPS estimate for 2026 is shown in the chart on this page when analysts have published one.
No reliable forecast exists that far out.
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Related: Telix Pharmaceuticals · Financials · Dividends · Compare · AI stocks
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.
$3.24B
Market Cap
—
P/E
—
Forward P/E
—
Score